MFG
NTLA icon

Menard Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Menard Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,392
Closed -$265K – 73
2023
Q3 		$265K Buy
+8,392
New +$326K 0.38% 59

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Menard Financial Group's NTLA Position: Q4 2023 in Review

Menard Financial Group sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 8,392 shares — an estimated $265K sold.

Menard Financial Group first reported a position in NTLA in Q3 2023 and held it in 1 quarter. The position peaked at $265K in Q3 2023. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

  • Menard Financial Group reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Menard Financial Group sold 8,392 Intellia Therapeutics shares in Q4 2023, an estimated $265K.
  • Menard Financial Group first reported a position in Intellia Therapeutics in Q3 2023 and held it in 1 quarter.
  • Menard Financial Group's Intellia Therapeutics position peaked at $265K in Q3 2023.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Menard Financial Group's 13F filing for Q4 2023, filed 14 Feb 2024.